Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Determination of stimulated beta-cell capacity in oral Nateglinide 50 g glucose tolerance test ("Nateglinide test")
2006-006384-24Phase 3Terminated
- Sponsor
- Goethe University Frankfurt
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nateglinide in type 2 diabetes mellitus (T2DM), sponsored by Goethe University Frankfurt. Primary endpoints: glucose, insulin and 1 more. Started Mar 2007; status: terminated.
02
Drugs
nateglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-006384-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006384-24.